These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 12543057)

  • 21. St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?
    Kholghi G; Arjmandi-Rad S; Zarrindast MR; Vaseghi S
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Jun; 395(6):629-642. PubMed ID: 35294606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperforin, the active component of St. John's wort, induces IL-8 expression in human intestinal epithelial cells via a MAPK-dependent, NF-kappaB-independent pathway.
    Zhou C; Tabb MM; Sadatrafiei A; Grün F; Sun A; Blumberg B
    J Clin Immunol; 2004 Nov; 24(6):623-36. PubMed ID: 15622447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. St. John's wort: a new alternative for depression?
    Josey ES; Tackett RL
    Int J Clin Pharmacol Ther; 1999 Mar; 37(3):111-9. PubMed ID: 10190758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1.
    Singer A; Wonnemann M; Müller WE
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1363-8. PubMed ID: 10454515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug interactions with St John's wort : mechanisms and clinical implications.
    Mannel M
    Drug Saf; 2004; 27(11):773-97. PubMed ID: 15350151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. St John's Wort (Hypericum perforatum)--a herbal antidepressant.
    Hippius H
    Curr Med Res Opin; 1998; 14(3):171-84. PubMed ID: 9787983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of oral administration of extracts of Hypericum perforatum (St John's wort) on brain serotonin transporter, serotonin uptake and behaviour in mice.
    Hirano K; Kato Y; Uchida S; Sugimoto Y; Yamada J; Umegaki K; Yamada S
    J Pharm Pharmacol; 2004 Dec; 56(12):1589-95. PubMed ID: 15563766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature].
    Bouron A; Lorrain E
    Encephale; 2014 Apr; 40(2):108-13. PubMed ID: 23816060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of a methanolic extract and a hyperforin-enriched CO2 extract of St. John's Wort (Hypericum perforatum) on intracerebral field potentials in the freely moving rat (Tele-Stereo-EEG).
    Dimpfel W; Schober F; Mannel M
    Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():30-5. PubMed ID: 9684945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [St. John's wort (Hypericum perforatum L.). A plant with relevance for dermatology].
    Schempp CM; Müller KA; Winghofer B; Schöpf E; Simon JC
    Hautarzt; 2002 May; 53(5):316-21. PubMed ID: 12063742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of serotonergic antidepressants and St John's wort in older Australians: a population-based cohort study.
    Rahman SZ; Basilakis J; Rahmadi A; Lujic S; Musgrave I; Jorm L; Hay P; Münch G
    Australas Psychiatry; 2013 Jun; 21(3):262-6. PubMed ID: 23439542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review.
    Whiskey E; Werneke U; Taylor D
    Int Clin Psychopharmacol; 2001 Sep; 16(5):239-52. PubMed ID: 11552767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products.
    Schulte-Löbbert S; Holoubek G; Müller WE; Schubert-Zsilavecz M; Wurglics M
    J Pharm Pharmacol; 2004 Jun; 56(6):813-8. PubMed ID: 15231048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mania during the use of a combination preparation with St. John's wort (Hypericum perforatum)].
    Güzelcan Y; Scholte WF; Assies J; Becker HE
    Ned Tijdschr Geneeskd; 2001 Oct; 145(40):1943-5. PubMed ID: 11675976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort.
    Friede M; Henneicke von Zepelin HH; Freudenstein J
    Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S38-41. PubMed ID: 11518073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study.
    Muruganandam AV; Bhattacharya SK; Ghosal S
    Indian J Exp Biol; 2001 Dec; 39(12):1302-4. PubMed ID: 12018529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
    Obach RS
    J Pharmacol Exp Ther; 2000 Jul; 294(1):88-95. PubMed ID: 10871299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin.
    Wang EJ; Barecki-Roach M; Johnson WW
    J Pharm Pharmacol; 2004 Jan; 56(1):123-8. PubMed ID: 14980009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Hypericum perforatum (St. John's wort) on passive avoidance in the rat: evaluation of potential neurochemical mechanisms underlying its antidepressant activity.
    Misane I; Ogren SO
    Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S89-97. PubMed ID: 11518084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort.
    Buchholzer ML; Dvorak C; Chatterjee SS; Klein J
    J Pharmacol Exp Ther; 2002 May; 301(2):714-9. PubMed ID: 11961077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.